Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

A recent CNN report cast a spotlight on Akeso, a Chinese biotech company whose immunotherapy ivonescimab drug, now in ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

The Jha brothers are accused of trafficking in various falsified medicines, including knock-offs of Merck & Co's Keytruda.